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1. INTRODUCTION {#cam42732-sec-0001}
===============

The 2016 revision of World Health Organization classification of lymphoid neoplasms defined marginal zone lymphoma (MZL) as a non‐Hodgkin lymphoma (NHL) that includes three distinct subtypes: extranodal MZL of mucosa‐associated lymphoid tissue (MALT), nodal, and splenic MZL.[1](#cam42732-bib-0001){ref-type="ref"} Together, they account for approximately 10% of NHL and are the third most common histological subtype of NHL after diffuse large B‐cell lymphoma (DLBCL) and follicular lymphoma.[2](#cam42732-bib-0002){ref-type="ref"}, [3](#cam42732-bib-0003){ref-type="ref"} They are grouped together because they arise from postgerminal center marginal zone B cells and share histopathologic and immunophenotypic features.[4](#cam42732-bib-0004){ref-type="ref"}, [5](#cam42732-bib-0005){ref-type="ref"}

MZL is considered an indolent lymphoma that typically occurs in association with autoimmune diseases and chronic inflammation and was first described by Isaacson and Wright as a low‐grade lymphoma of gastrointestinal tract MALT.[6](#cam42732-bib-0006){ref-type="ref"}, [7](#cam42732-bib-0007){ref-type="ref"} This is the most common site of origin where lymphoproliferation is associated with longstanding autoantigenic stimulation due to the action of *Helicobacter pylori* and other microbes.[3](#cam42732-bib-0003){ref-type="ref"}, [8](#cam42732-bib-0008){ref-type="ref"} MZL can originate from the mucosa of nongastrointestinal organs such as lung, bladder, salivary glands, conjunctiva, and lacrimal glands.[3](#cam42732-bib-0003){ref-type="ref"} Interestingly, MZL can also develop from tissue sites without mucosa including liver, breast, thyroid, orbit, skin, and the central nervous system (CNS).[3](#cam42732-bib-0003){ref-type="ref"}, [9](#cam42732-bib-0009){ref-type="ref"} Meningoepithelial cells of the arachnoid villi of dural venous sinuses could represent the cells of origin of CNS MZL where MALT‐type tissue develops secondary to chronic inflammation which provides a milieu for local accumulation and proliferation of antigen‐dependent B cells, leading to lymphoma development.[10](#cam42732-bib-0010){ref-type="ref"} Due to rarity, the clinical features and optimal management of CNS MZL are not well defined. To address this, we performed a retrospective study to describe the clinical characteristics, prognostic factors, treatment, and outcomes of patients with MZL and primary or secondary CNS involvement. We recognize that CNS MZL is truly defined by the presence of parenchymal and/ or leptomeningeal involvement, however, we have included patients with dural MZL in this analysis to describe the clinical features and response to treatment of this disease also.

2. METHODS {#cam42732-sec-0002}
==========

We searched institutional databases (MD Anderson Cancer Center; Sir Charles Gairdner Hospital; Aalborg University Hospital) and regional or national databases (BC Cancer Centre for Lymphoid Cancer database, Canada; Swedish Lymphoma Registry) to identify patients with CNS MZL who met the following inclusion criteria: (a) histopathologic diagnosis of MZL (b) histologically proven MZL of the dura, brain, or leptomeninges, or cytologically proven cerebrospinal fluid involvement at any time during disease course and (c) initial diagnosis of MZL between 1995 and 2018. Pathology review was performed by specialist hematopathologist at each listed center. Those with suspected DLBCL were excluded from analysis.

We collected baseline demographic and clinical data, treatment, and outcomes. Statistical analysis was performed using STATA 14.2 (STATA Corp). In patients with MZL and secondary CNS involvement, time to CNS involvement was calculated from date of systemic MZL diagnosis to date of confirmed CNS involvement. Median observation period was calculated from the median observation time of patients alive at last follow‐up. Overall survival (OS) was defined as time from CNS involvement to date of death with patients alive at last follow‐up censored. Progression‐free survival (PFS) was defined as the time of diagnosis of CNS disease to disease progression or death from any cause, with patients free from progression at that time point censored. Survival data were analyzed using the method of Kaplan‐Meier. Data collection was compliant with institutional requirements.

3. RESULTS {#cam42732-sec-0003}
==========

A total of 26 patients with histologically confirmed CNS MZL were identified. Clinical features at diagnosis with MZL and outcomes are summarized in Table [1](#cam42732-tbl-0001){ref-type="table"}. Half had primary CNS MZL at diagnosis, whereas the remaining half had secondary CNS MZL. Of the 13 patients with primary CNS MZL, 12 had biopsy proven MZL and for the remaining patient the specific method of detection was not documented. For the 13 patients with secondary CNS MZL, seven had biopsy proven MZL, whereas the remaining six had cytological evidence of MZL in CSF (3 of these had flow cytometric confirmation, for three patients the specific method of disease detection beyond cytology was not documented).

###### 

Baseline characteristics

  Features                          Overall n = 26 (%)   Primary (n = 13)   Secondary (n = 13)
  --------------------------------- -------------------- ------------------ --------------------
  Age                                                                       
  Median                            59.5 y               51 y               62 y
  Range                             26‐78 y              26‐78 y            34‐77 y
  Sex                                                                       
  Female                            16 (62)              9                  7
  Male                              10 (38)              4                  6
  ECOG                                                                      
  0                                 16 (62)              9                  7
  1                                 7 (27)               3                  4
  2                                 1 (4)                1                  0
  3                                 2 (8)                0                  2
  Stage at original MZL diagnosis                                           
  I                                 12 (46)              11                 1
  II                                2 (8)                1                  1
  III                               0                    0                  0
  IV                                12 (46)              1                  11
  B symptoms                                                                
  Present                           2 (8)                0                  2
  Absent                            23 (88)              13                 10
  Missing                           1 (4)                0                  1
  CNS location                                                              
  Dural only                        13 (50)              9                  4
  Parenchymal only                  5 (19)               3                  2
  Leptomeningeal only               1 (4)                0                  1
  Other                             3 (12)               0                  3
  Missing                           4 (15)               1                  3
  Serum LDH                                                                 
  Normal                            16 (62)              9                  7
  Elevated                          7 (27)               3                  4
  Missing                           3 (12)               1                  2
  Treatment                                                                 
  RTx alone                         1 (4)                0                  1
  CTx alone                         5 (19)               0                  5
  SX + RTx                          7 (27)               5                  2
  SX + CTx                          6 (23)               4                  2
  RTx + CTx                         0                    0                  0
  SX + RTx +CTx                     4 (15)               3                  1
  Missing                           3 (12)               1                  2
  PF event                                                                  
  No                                13 (50)              11                 2
  Yes                               10 (38)              2                  8
  Missing                           3 (12)               0                  3
  Outcome                                                                   
  Alive                             22 (85)              13                 9
  Dead                              4 (15)               0                  4

Data expressed as number (percentage).

Abbreviations: CTx, chemotherapy; LDH, lactate dehydrogenase; PF, progression free; RTx, radiotherapy; SX, surgery.
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Of the 26 patients, 16 (62%) were female and the median age at diagnosis was 59.5 years (range of 26‐78). Most patients had good performance status at diagnosis (ECOG ≤ 1). All patients for which information was available presented with focal neurological symptoms including sensory loss, extremity weakness, visual changes, seizures and/or headaches. This is summarized in Table [2](#cam42732-tbl-0002){ref-type="table"}. Median duration of symptoms prior to CNS diagnosis was 105 days (range 30‐420) for primary disease and 60 days (range 0‐930 days) for secondary disease. Only two patients (8%) had B type symptoms at presentation and these patients had secondary CNS MZL stage IV disease with leptomeningeal involvement.

###### 

Patient characteristics, treatment and outcome

  No   Age/sex   Primary/Secondary   ECOG   LDH        BSx       Presentation                                             Site                                                                                Treatment      CTX Type                     CNS Response   Status   OS (y)
  ---- --------- ------------------- ------ ---------- --------- -------------------------------------------------------- ----------------------------------------------------------------------------------- -------------- ---------------------------- -------------- -------- ---------
  1    38/F      Primary             0      Normal     No        Altered sensation bilateral upper limbs                  C6 intramedullary cord                                                              SX, CTx, RTx   MTX                          CRu            Alive    1.4
  2    78/F      Primary             1      Normal     No        Left hemiparesis                                         Right frontotemporal and parietal dura invading skull and temporalis muscle         SX, CTx        R‐CHOP + MTX                 CRu            Alive    0.54
  3    51/F      Primary             0      Unknown    No        Personality change                                       Left frontal dura                                                                   SX, CTx        R‐CHOP + MTX                 CR             Alive    2.05
  4    51/M      Primary             2      Normal     No        Unknown                                                  Unknown                                                                             Unknown        N/A                          CRu            Alive    2.41
  5    26/M      Primary             0      Normal     No        Altered sensation face                                   Left medial temporal lobe dura                                                      SX, CTx        R‐CHOP                       CR             Alive    9.49
  6    62/M      Primary             0      Normal     No        Seizure                                                  Left fronto‐parietal region dura                                                    SX, CTx, RTx   R                            CR             Alive    3.84
  7    54/F      Primary             0      Normal     No        Visual changes                                           Dura overlying tuberculum sella, suprasellar cistern, sella turcica                 SX, RTx        N/A                          CR             Alive    5.15
  8    34/M      Primary             0      Normal     No        Seizure                                                  Right temporal lobe                                                                 SX, RTx        N/A                          CR             Alive    8.22
  9    78/F      Primary             1      Elevated   No        Headaches                                                Dura of overlying cavernous sinus                                                   SX, CTx        BR + MTX (IT) / Ara‐C (IT)   Unknown        Alive    0.34
  10   30/F      Primary             0      Elevated   No        Diplopia and ptosis                                      Dura overlying cavernous sinus                                                      SX, RTx        N/A                          PR             Alive    1.89
  11   66/F      Primary             1      Elevated   No        Left facial palsy and left hemiparesis                   Right basal ganglia                                                                 SX, CTx, RTx   R + MTX                      Progressive    Alive    1.76
  12   50/F      Primary             0      Normal     No        Altered sensation                                        Dura overlying left temporal region                                                 SX, RTx        N/A                          CRu            Alive    0.41
  13   61/F      Primary             0      Normal     No        Seizure, speech disturbance                              Dura of left cerebral convexity                                                     SX, RTx        N/A                          CRu            Alive    1.15
  14   77/M      Secondary           0      Normal     Present   Visual loss                                              Left optic nerve                                                                    CTx            R‐CHOP + MTX (IT)            Died           Dead     0.1
  15   59/M      Secondary           0      Normal     No        Scalp swelling, dysarthria                               Right frontoparietal dura                                                           CTx            CVPR                         CR             Alive    11.44
  16   66/F      Secondary           3      Elevated   Present   Headaches, fevers, fatigue                               Frontal lobe, occipital lobe, cerebellum                                            CTx            MTX (IT) + Ara‐C (IT)        PR             Dead     0.583
  17   53/F      Secondary           3      Unknown    Unknown   Unknown                                                  Left frontal lobe                                                                   RTx            N/A                          PR             Dead     1.74
  18   66/M      Secondary           0      Elevated   No        Visual changes                                           Right posterior parieto‐occipital lobe                                              SX, RTx        N/A                          Died           Dead     0.16
  19   67/F      Secondary           0      Normal     No        Unknown                                                  Unknown                                                                             Unknown        N/A                          Unknown        Alive    3.01
  20   67/M      Secondary           1      Normal     No        Unknown                                                  Unknown                                                                             Unknown        N/A                          PR             Alive    1.34
  21   46/F      Secondary           0      Normal     No        Unknown                                                  Unknown                                                                             CTx            FDR + Ara‐C                  CRu            Alive    3.45
  22   57/F      Secondary           0      Unknown    No        Personality change, unsteadiness, memory loss            Surrounding lateral and third ventricles                                            CTx            IFO + Ara‐C + MTX            Unknown        Alive    Unknown
  23   34/M      Secondary           0      Elevated   No        Altered sensation                                        Dural based sacral spinal canal                                                     SX, CTx, RTx   R‐CHOP                       CR             Alive    4.22
  24   62/M      Secondary           1      Normal     No        Headaches, pain in V2 distribution of trigeminal nerve   Dura overlying optic nerves, pterygopalatine fossa, cavernous sinus, optic chiasm   SX, CTx        R                            Progressive    Alive    1.57
  25   69/F      Secondary           1      Elevated   No        Visual changes                                           Dura of right orbit and skull base                                                  SX, RTx        N/A                          Progressive    Alive    1.6
  26   60/F      Secondary           1      Normal     No        Altered sensation                                        Skull base leptomeinges and extradural space C2‐C4                                  SX, CTx        Ibrutinib + R                Unknown        Alive    0.09

Abbreviations: Ara‐C, cytarabine; BR, bendamustine rituximab; BSx, B symptoms; CR complete response; Cru, complete response unconfirmed; CTx, chemotherapy; CVPR, cyclophosphamide, vincristine, prednisolone, rituximab; F, female; FDR, fludarabine; IFO, ifosfamide; IT, intrathecal; M, male; MTX, methotrexate; N/A, not applicable; OS, overall survival; PR, partial response; Progressive, progressive disease; R, rituximab; R‐CHOP, rituximab, cyclophosphamide, vincristine, doxorubicin, prednisolone; RTx, radiotherapy; SX, surgery.

John Wiley & Sons, Ltd

Most patients with primary disease had stage I disease (n = 11) at time of original diagnosis. One patient with primary disease had MZL invading the skull and temporalis muscle and was classified as stage IV disease. Most patients with secondary MZL had stage IV disease (n = 11) at time of original diagnosis. The most common anatomical location of MZL was disease isolated to dura (50%). This was also the most common site of disease for those with primary CNS MZL (n = 9, 69%). For those with secondary CNS involvement; four (31%) had disease limited to the dura, whereas two (15%) had parenchymal only disease, one (4%) had disease limited to the leptomeninges, two (15%) had parenchymal + leptomeningeal disease, and one (4%) had leptomeningeal + optic nerve involvement. Data were not available for disease location for one patient with primary and three with secondary CNS involvement.

A minority (n = 7, 27%) of patients presented with elevated serum LDH. All patients, for whom data were available (n = 19), were negative for HIV, Hepatitis B and C. With respect to investigations, lumbar puncture was performed in 20 cases (77%) and lymphoma cells were detected in the cerebrospinal fluid in 3/20 (15%) using cytology and flow cytometry. Positron emission tomography (PET) scan was performed in 18 cases (69%), for which information was available. Magnetic resonance imaging (MRI) of the head was performed in all cases for which information was available (n = 22) and 20 patients (77%) had unifocal disease, whereas two (8%) patients, both with secondary CNS MZL, had multifocal disease. Of patients with secondary CNS MZL, six (46%) had evidence of bone marrow involvement at time of documented CNS dissemination.

Treatment was at the discretion of the treating physician and is outlined in Table [1](#cam42732-tbl-0001){ref-type="table"}. Overall the most common treatment was surgery + radiotherapy (n = 7, 27%). For primary disease, the most common treatment modality was surgery + radiotherapy (n = 5). Treatment data were not known for one patient with primary disease. With respect to the type of surgery performed, those with dural limited disease had complete resection and those with parenchymal disease had craniotomy and biopsy. Seven patients with primary disease that received systemic therapy were treated with a combination of methotrexate and/or rituximab (either alone or in combination with cyclophosphamide, doxorubicin, vincristine, prednisolone \[R‐CHOP\]). One patient was treated with bendamustine, rituximab, and alternating intrathecal cytarabine and intrathecal methotrexate. No patient with primary disease was treated with radiotherapy or chemotherapy alone. Table [2](#cam42732-tbl-0002){ref-type="table"} outlines the specific treatment for each patient.

Of the 13 patients with secondary CNS MZL, eight (62%) had CNS involvement at the time of initial diagnosis of MZL. Of the remaining five cases who developed CNS involvement at a later stage, four had received treatment prior to diagnosis of CNS. The most common treatment modality for secondary disease was chemotherapy alone (n = 5). Methotrexate, rituximab, and cytarabine were used in various combinations for those with secondary disease. Other combinations included R‐CHOP, fludarabine + cytarabine, ifosfamide + cytarabine +methotrexate, and ibrutinib + rituximab.

For patients with primary CNS MZL, complete CNS response was achieved in 10 (77%) of 13 patients. No patient with primary disease had systemic progression. For patients with secondary disease, only three (23%) of 13 achieved complete CNS response. Two of these patients were treated with chemotherapy alone, whereas the other was treated with all three modalities. Four patients died, all with systemically progressive secondary CNS MZL. One died from an acute on chronic subdural hemorrhage complicating neutropenic sepsis, whereas the remaining three died from progressive lymphoma, one of which showed transformation to a high‐grade lymphoma. All patients with MZL localized to the dura were alive at last follow‐up. Best CNS response to treatment was unknown for four patients (1 with primary disease and 3 with secondary).

After a median follow‐up time of 1.9 years (range 0.1‐11.4 years), the overall median PFS was not reached with 2‐year PFS of 59% (95%CI:34%‐77%) (Figure [1](#cam42732-fig-0001){ref-type="fig"}A). The estimated 2‐year overall survival rate was 80% (95%CI:54%‐92%) (Figure [1](#cam42732-fig-0001){ref-type="fig"}B). Overall survival for primary disease at 2 years was 100%, whereas for secondary CNS MZL this was 58%.

![A, Kaplan‐Meir estimate of PFS (in years), B, Kaplan‐Meir estimate of OS (in years)](CAM4-9-663-g001){#cam42732-fig-0001}

4. DISCUSSION {#cam42732-sec-0004}
=============

In this series of patients with MZL, we confirm the relatively favorable outcome of primary CNS MZL and report the inferior prognosis associated with secondary CNS involvement. CNS MZL typically presents as a solitary mass occupying lesion that arises from the dura without systemic disease involvement.[3](#cam42732-bib-0003){ref-type="ref"}, [11](#cam42732-bib-0011){ref-type="ref"} It is a rare form of primary CNS lymphoma (PCNSL) and has a better prognosis compared to the more common primary CNS DLBCL.[12](#cam42732-bib-0012){ref-type="ref"}, [13](#cam42732-bib-0013){ref-type="ref"} In a recent SEER analysis of outcomes of primary CNS lymphoma by histologic subtype, the 5‐year OS rates were 30% (95%CI:28%‐32%) for DLBCL and 79% (95%CI:64%‐88%) for MZL.[12](#cam42732-bib-0012){ref-type="ref"} In this study, reported outcomes for CNS MZL were comparable with estimated 2‐year OS 80% (95%CI:54%‐92%). Patients with secondary CNS MZL appear less likely to achieve CNS complete response, and have inferior PFS and OS. There may be some factors that are associated with this inferior OS such as the advanced stage of disease at diagnosis, poor performance status, B symptoms, and experiencing a progression‐free survival event. Due to limited sample size we did not perform univariate analysis so cannot comment on the statistical significance of these associations compared to those with primary CNS MZL.

Due to the rarity of MZL, there have been no trials that evaluate different treatment options, and therefore there are no standardized treatment regimens for clinicians to utilize. There are only a few cases series of secondary MZL in the existing literature.[3](#cam42732-bib-0003){ref-type="ref"}, [14](#cam42732-bib-0014){ref-type="ref"}, [15](#cam42732-bib-0015){ref-type="ref"} With respect to treatment of primary disease, it is known that MZL is very radiosensitive and it has been suggested that patients with disease isolated to the dura may not require systemic chemotherapy.[16](#cam42732-bib-0016){ref-type="ref"} In a combined series from Memorial Sloan Kettering Cancer Center and the University of Miami, of 23 patients with dural MZL treated after biopsy or surgery, 22 achieved a complete remission.[17](#cam42732-bib-0017){ref-type="ref"} The majority of patients (87%) received cranial directed radiation therapy as a component of therapy and the 3‐year PFS was 89%.[17](#cam42732-bib-0017){ref-type="ref"} Only four patients received systemic therapy prompting the authors to conclude that complete remission is achievable with focal therapy in this indolent disease. A recent review by Chihara et al showed that localized treatment with radiotherapy ± surgery was the most common therapeutic approach for patients with primary MZL.[12](#cam42732-bib-0012){ref-type="ref"} Our data are consistent with this.

All patients with primary CNS MZL were alive at median follow‐up time, aligning with the more indolent nature of this disease. Only two patients with primary disease did not achieve complete CNS response. Given the lack of treatment experience with respect to CNS MZL, and even more so with secondary CNS disease, it is not surprising that such a range of modalities were chosen based on disease location and patient characteristics. As opposed to radiotherapy ± surgery, chemotherapy was the most common treatment modality for secondary CNS MZL, in keeping with physician selected treatment for more aggressive lymphomas.

The dura was the most common site of CNS MZL involvement, consistent with other case series.[13](#cam42732-bib-0013){ref-type="ref"} Cases of primary MZL involving the CNS parenchyma and leptomeninges are rare.[7](#cam42732-bib-0007){ref-type="ref"}, [9](#cam42732-bib-0009){ref-type="ref"}, [16](#cam42732-bib-0016){ref-type="ref"} No case of primary CNS MZL in this study had leptomeningeal involvement, but three cases involved the parenchyma including the intramedullary cord, temporal lobe and basal ganglia. The anatomic location of secondary CNS MZL was more varied and suggests that MZL with systemic involvement is more heterogenous and more likely to involve the parenchyma and leptomeninges. It is an important clinical consideration that the majority of cases of secondary CNS MZL in this study presented as unifocal disease that could easily be mistaken as a primary dural lymphoma unless thorough assessment of systemic involvement was performed.

Regarding distribution according to sex, we demonstrated a female preponderance and that this tendency may be less pronounced with respect to secondary MZL where the female to male ratio was smaller. Another difference between primary and secondary disease was the median age of diagnosis. Interestingly, there was an 11‐year difference between the median age of diagnosis for primary (51 years) and secondary (62 years) disease. Therefore, while the overall median age of diagnosis in our study (59.5 years) was similar to previously published studies, secondary involvement of CNS tissue by MZL appeared to occur in a slightly older cohort than for primary disease.[13](#cam42732-bib-0013){ref-type="ref"} This aligns with the data published by Khalil and colleagues on 8,821 cases of MZL from multiple anatomical sites that had a median age of diagnosis of 66 years.[18](#cam42732-bib-0018){ref-type="ref"} The time to CNS diagnosis was also a point of difference, however the much shorter duration of symptoms prior to detection of CNS disease in patients with secondary CNS MZL was unsurprising given these patients had a pre‐existing diagnosis of MZL or presented with widespread symptomatic disease.

There are some limitations to this study. Given the rarity of the disease, the sample size was small which limited the application of multivariable analysis. The median follow‐up time of 1.9 years could be considered short given the range over which patients were assessed. Furthermore, due to this long period of inclusion eligibility (1995‐2018), treatment modalities used may not be reflective of current practice. Finally, there were some data points that could not be collected.

5. CONCLUSION {#cam42732-sec-0005}
=============

MZL with secondary CNS involvement has an older age, less female predominance, more variable CNS localization and inferior prognosis relative to primary CNS MZL. Patients with primary MZL have favorable outcomes with radiotherapy. It also appears that patients with dural location of MZL have a better outcome. The optimal treatment of secondary CNS MZL remains unclear, though the use of CNS penetrating chemotherapeutics appears reasonable.
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